These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Comparison of three pathologic classifications (Rappaport, LSG and Working Formulation) for the treatment of non-Hodgkin's lymphoma]. Shibuya H; Kamiyama R; Umehara I; Okada Y; Sato S; Yoshimatsu S; Horiuchi J; Suzuki S Gan No Rinsho; 1985 Nov; 31(14):1757-61. PubMed ID: 4087381 [TBL] [Abstract][Full Text] [Related]
23. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938 [TBL] [Abstract][Full Text] [Related]
24. DNA-protein flow cytometric analysis in non-Hodgkin lymphoma. Del Bino G; Silvestrini R; Costa A; Mazzini G; Giordano P Basic Appl Histochem; 1987; 31(2):183-90. PubMed ID: 2443119 [TBL] [Abstract][Full Text] [Related]
25. [Expression and clinical significance of nm23-H1 and MUC-1 in peripheral T-cell lymphoma]. Huang HQ; Pan ZH; Lin XB; Wang BF; Hou JH; Zhang Y; Wu QL Ai Zheng; 2006 Dec; 25(12):1517-23. PubMed ID: 17166378 [TBL] [Abstract][Full Text] [Related]
26. Histologic classification and immunophenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T cell lymphomas with B cell morphology. Teske E; Wisman P; Moore PF; van Heerde P Exp Hematol; 1994 Nov; 22(12):1179-87. PubMed ID: 7925781 [TBL] [Abstract][Full Text] [Related]
27. Histologic subtypes and survival of Chinese patients with non-Hodgkin's lymphomas. Liang R; Loke SL; Ho FC; Chiu E; Chan TK; Todd D Cancer; 1990 Oct; 66(8):1850-5. PubMed ID: 2208041 [TBL] [Abstract][Full Text] [Related]
28. Modification of Kiel and working formulation classifications for improved survival prediction in non-Hodgkin's lymphoma. Nabholtz JM; Friedman S; Collin F; Guerrin J J Clin Oncol; 1987 Oct; 5(10):1634-9. PubMed ID: 3655861 [TBL] [Abstract][Full Text] [Related]
29. Comparison of the working formulation of non-Hodgkin's lymphoma with the Rappaport, Kiel, and Lukes & Collins classifications. Translational value and prognostic significance based on review of 658 patients treated at a single institution. Ersbøll J; Schultz HB; Hougaard P; Nissen NI; Hou-Jensen K Cancer; 1985 May; 55(10):2442-58. PubMed ID: 3986740 [TBL] [Abstract][Full Text] [Related]
30. Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material. Rabenhorst SH; Burini RC; Schmitt FC Pathology; 1996 Jan; 28(1):12-6. PubMed ID: 8714262 [TBL] [Abstract][Full Text] [Related]
31. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis. Akerman M; Brandt L; Johnson A; Olsson H Br J Cancer; 1987 Feb; 55(2):219-23. PubMed ID: 3814492 [TBL] [Abstract][Full Text] [Related]
32. Cell proliferation and DNA content in non-Hodgkin's lymphoma. Flow cytometry in relation to lymphoma classification. Christensson B; Tribukait B; Linder IL; Ullman B; Biberfeld P Cancer; 1986 Sep; 58(6):1295-304. PubMed ID: 3742454 [TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of [3H]-thymidine labelling index and monoclonal antibody Ki-67 in non-Hodgkin's lymphomas. Veneroni S; Costa A; Motta R; Giardini R; Rilke F; Silvestrini R Hematol Oncol; 1988; 6(1):21-8. PubMed ID: 3343026 [TBL] [Abstract][Full Text] [Related]
34. Relation between enzymatic activities and the degree of malignancy of human lymphomas. Vezzoni P; Giardini R; Raineri M; Pozzi MR; Lucchini R; Vezzoni MA; Clerici L; Besana C; Rugarli C; Rilke F Eur J Cancer Clin Oncol; 1985 Aug; 21(8):945-50. PubMed ID: 4043177 [TBL] [Abstract][Full Text] [Related]
35. [On the dissemination of B-cell non-Hodgkin lymphomas at the time of diagnosis]. Pap T; Vogt U; Waldinger K; Kelényi G Zentralbl Allg Pathol; 1982; 126(3-4):321-6. PubMed ID: 7148187 [TBL] [Abstract][Full Text] [Related]
36. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas. Lehtinen T Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829 [TBL] [Abstract][Full Text] [Related]
37. Prognostic implications of cell kinetics, histopathology and pathologic stage in non-Hodgkin's lymphomas. Silvestrini R; Costa A; Giardini R; Boracchi P; Del Bino G; Marubini E; Rilke F Hematol Oncol; 1989; 7(6):411-22. PubMed ID: 2807179 [TBL] [Abstract][Full Text] [Related]
38. A new working formulation of non-Hodgkin's lymphomas. A retrospective study of the new NCI classification proposal in comparison to the Rappaport and Kiel classifications. Krueger GR; Medina JR; Klein HO; Konrads A; Zach J; Rister M; Janik G; Evers KG; Hirano T; Kitamura H; Bedoya VA Cancer; 1983 Sep; 52(5):833-40. PubMed ID: 6871825 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of malignant lymphomas using three classifications and the working formulation. 482 cases with median follow-up of 11.9 years. Lieberman PH; Filippa DA; Straus DJ; Thaler HT; Cirrincione C; Clarkson BD Am J Med; 1986 Sep; 81(3):365-80. PubMed ID: 3752139 [TBL] [Abstract][Full Text] [Related]
40. Ploidy and proliferative activity measurement by flow cytometry in non-Hodgkin's lymphomas. Do speculative aspects prevail over clinical ones? Cavalli C; Danova M; Gobbi PG; Riccardi A; Magrini U; Mazzini G; Bertoloni D; Rutigliano L; Rossi A; Ascari E Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1755-63. PubMed ID: 2632257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]